GE_Healthcare_is_Predicting_a 1 Trillion Dollar Marketplace by_2025
for Regenerative Medical Therapy. "Could cell therapy be a trillion dollar industry by 2025? GE thinks so..." link below (I love this story. A TRILLION Dollar Market, heh!)
GE is one of the most successful organizations in human history. And for GE Healthcare to make such a bold prediction is hugely significant. This cannot be casually dismissed, not validly.
A Trillion Dollars in ten years, is a hundred billion growth each year.
OCAT has the FIRST regenerative therapy that is FDA Approved!
Being first through the FDA gauntlet is nothing to be dismissed lightly. This represents two things.
Firstly, it highlights the ENORMOUS lead that OCAT enjoys over EVERYONE !
Second, it places OCAT in the position of the Marketplace Gold Standard Bearer. OCAT has worked with the FDA to invent the regulatory protocols that all future cell therapy will be judged against.
This will be rewarded in the marketplace with a market cap not yet imagined, and right now too scary to contemplate.
Phase 1 confirms everything going on here. Complete safety, with indications of efficacy, is hugely significant. This cannot be casually dimissed, not validly. The FDAs own guidelines, state that phase 1 trials vary from 20 to 80 patients. OCATs 40 patient phase 1 trial is completely reasonable, and is more or less typical in size. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.21
There's more work to do, but there's every reason, every indication, to look positively upon OCAT.
GE Healthcare looks positively upon the entire ReGen marketplace, of which OCAT is the unchallenged leader.
OCAT has the FIRST regenerative therapy that is FDA Approved!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.